Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New sealant could cut chest tube time for lung cancer patients

NCT ID NCT07479277

Disease control Sponsor: Fondazione del Piemonte per l'Oncologia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether applying a surgical sealant (Progel Platinum) to staple lines during lung cancer surgery can reduce the time patients need a chest tube. About 160 adults having minimally invasive lung lobectomy for non-small cell lung cancer will be randomly assigned to get the sealant plus staples or staples alone. The main goal is to see if the sealant shortens chest tube duration and hospital stay.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Progel Platinum surgical sealant
What this could lead to
If it works, this could mean fewer days with a chest tube and a shorter hospital stay after lung cancer surgery.
What could go wrong
This is a relatively small, early-stage trial. The sealant may not significantly reduce drainage time, and there is a risk of allergic reaction or other complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 160 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Written informed consent * Planned VATS upper or lower lobectomy for NSCLC * Minimally invasive thoracoscopic approach * Middle lobectomy excluded Exclusion Criteria: * Induction radiochemotherapy or chemo-immunotherapy * Severe COPD: GOLD 3 or higher * Sleeve resection or extended resection involving other lobes/chest wall/pericardium, etc. * Albumin intolerance/allergy * Renal insufficiency * Redo surgery * Use of sealants/adhesives other than the study approach * Expected extensive pleural adhesions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-small cell lung cancer NSCLC Postoperative air leak

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Azienda Ospedaliera-Universitaria Pisana

    NOT_YET_RECRUITING

    Pisa, Italy

  • Azienda Ospedaliero-Universitaria Careggi

    NOT_YET_RECRUITING

    Florence, Italy

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

    NOT_YET_RECRUITING

    Milan, Italy

  • Irccs Ismett

    NOT_YET_RECRUITING

    Palermo, Italy

  • Ospedale centrale di Bolzano, Chirurgia Toracica e Vascolare

    NOT_YET_RECRUITING

    Bolzano, Italy

  • Unità di Chirurgia Toracica Oncologica

    RECRUITING

    Candiolo, Torino, 10060, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.